# Atezolizumab

## Tecentriq inj 1200mg/20mL

##### 臨採

| TAH Drug Code      | [ITEC](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITEC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Locally advanced or metastatic urothelial carcinoma (UC) after prior chemotherapy, or for those considered cisplatin ineligible & whose tumours have a PD-L1 expression ?5%, or those not eligible for any platinum-containing chemotherapy regardless of tumor PD-L1 expression level. 1st-line treatment in combination w/ bevacizumab, paclitaxel & carboplatin for metastatic non-squamous non-small cell lung cancer (NSCLC) w/ no EGFR or ALK genomic tumor aberrations. Locally advanced or metastatic NSCLC after prior chemotherapy. Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in combination w/ nab-paclitaxel, for those whose tumors have PD-L1 expression ?1% & who have not received prior chemotherapy for metastatic disease.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | 840 mg IV every 2 weeks or 1200 mg IV every 3 weeks, or 1680 mg IV every 4 weeks infused over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.  [Non-squamous NSCLC] In combination with bevacizumab, paclitaxel, & carboplatin: 1200 mg by IV infusion, followed by bevacizumab, paclitaxel, & then carboplatin every 3 weeks for 4 or 6 cycles during induction phase, then, followed by maintenance phase without chemotherapy and bevazicumab, in which 840 mg IV every 2 weeks or 1200 mg IV every 3 weeks, or 1680 mg IV every 4 weeks.  [Triple-negative breast cancer] In combination with nab-paclitaxel: 840 mg by IV infusion, followed by 100 mg/m2 nab-paclitaxel. For each 28-day cycle Tecentriq is administered on days 1 & 15, & nab-paclitaxel is administered on days 1, 8 & 15.  [Small cell lung cancer, SCLC] 1200 mg by IV infusion, followed by carboplatin AUC 5 mg/mL/min IV on day 1 and etoposide 100 mg/m2 IV on days 1 through 3 of each 21-day cycle for maximum of 4 cycles.  [Liver carcinoma] 1200 mg by IV infusion, followed by 15mg/kg bevacizumab every 3 weeks; continue until disease progression or unacceptable toxicity. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Diarrhea, nausea, vomiting, constipation; fatigue, asthenia, pyrexia, headache; UTI, lung infection; decreased appetite, hypomagnesemia; arthralgia, back pain, musculoskeletal pain; cough, dyspnea; rash, pruritus; anemia, neutropenia, thrombocytopenia; hypothyroidism; dizziness, peripheral neuropathy. Thrombocytopenia, decreased lymphocyte count; hypothyroidism, hyperthyroidism; dysphagia, colitis, abdominal pain, oropharyngeal pain, stomatitis; chills, flu-like illness, infusion-related reaction; increased ALT & AST, hepatitis; hypersensitivity; hypokalemia, hyponatremia, hyperglycemia; hypoxia, nasal congestion, pneumonitis, nasopharyngitis, dysphonia; hypotension; dysgeusia, syncope; proteinuria.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

